Literature DB >> 21457231

Severe α-1 antitrypsin deficiency caused by Q0(Ourém) allele: clinical features, haplotype characterization and history.

L Vaz Rodrigues1, F Costa, P Marques, C Mendonça, J Rocha, S Seixas.   

Abstract

α-1 Antitrypsin deficiency (AATD) caused by null alleles is associated with the total lack of protein and generally it translates into more severe clinical features of pulmonary disease. This is the case of Q0(Ourém) , a rare variant found in several families of Central Portugal caused by the L353fsX376 mutation. A total of 41 patients carrying at least one copy of Q0(Ourém) were evaluated for SERPINA1 levels, respiratory function values and lung parenchyma status (chest X-ray and computerized tomography scan). Q0(Ourém) haplotype background was characterized using seven microsatellites flanking SERPINA1 and Q0(Ourém) age was estimated by a statistical method relying on the decay of haplotype sharing at linked markers (DHSMAP). Homozygous patients showed a compromised lung function and extensive emphysema. SQ0(Ourém) , although having serum levels below the 11 µM threshold, did not necessarily result in signs of disease. MQ0(Ourém) were found to be a heterogeneous group, mainly composed of normal individuals. Eight Q0(Ourém) haplotypes were identified and the allele was estimated to have arisen 650 years ago. Q0(Ourém) was associated with mild to severe AATD and has a single origin, probably linked to the major Ourém settlements where the occurrence of severe AATD may not be explained by recent consanguinity.
© 2011 John Wiley & Sons A/S.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21457231     DOI: 10.1111/j.1399-0004.2011.01670.x

Source DB:  PubMed          Journal:  Clin Genet        ISSN: 0009-9163            Impact factor:   4.438


  7 in total

1.  Can we change a genetically determined future?

Authors:  Lígia Rodrigues Fernandes; Luis Vaz Rodrigues; Filipa Costa; Yvette Martins
Journal:  BMJ Case Rep       Date:  2015-05-15

Review 2.  Why has it been so difficult to prove the efficacy of alpha-1-antitrypsin replacement therapy? Insights from the study of disease pathogenesis.

Authors:  Jennifer A Dickens; David A Lomas
Journal:  Drug Des Devel Ther       Date:  2011-08-17       Impact factor: 4.162

3.  Deficient and Null Variants of SERPINA1 Are Proteotoxic in a Caenorhabditis elegans Model of α1-Antitrypsin Deficiency.

Authors:  Erin E Cummings; Linda P O'Reilly; Dale E King; Richard M Silverman; Mark T Miedel; Cliff J Luke; David H Perlmutter; Gary A Silverman; Stephen C Pak
Journal:  PLoS One       Date:  2015-10-29       Impact factor: 3.240

4.  Identification and characterisation of eight novel SERPINA1 Null mutations.

Authors:  Ilaria Ferrarotti; Tomás P Carroll; Stefania Ottaviani; Anna M Fra; Geraldine O'Brien; Kevin Molloy; Luciano Corda; Daniela Medicina; David R Curran; Noel G McElvaney; Maurizio Luisetti
Journal:  Orphanet J Rare Dis       Date:  2014-11-26       Impact factor: 4.123

Review 5.  Known Mutations at the Cause of Alpha-1 Antitrypsin Deficiency an Updated Overview of SERPINA1 Variation Spectrum.

Authors:  Susana Seixas; Patricia Isabel Marques
Journal:  Appl Clin Genet       Date:  2021-03-22

6.  The Clinical Utility of Determining the Allelic Background of Mutations Causing Alpha-1 Antitrypsin Deficiency: The Case with the Null Variant Q0(Mattawa)/Q0(Ourém).

Authors:  Judith Bellemare; Nathalie Gaudreault; Kim Valette; Irene Belmonte; Alexa Nuñez; Marc Miravitlles; François Maltais; Yohan Bossé
Journal:  Chronic Obstr Pulm Dis       Date:  2021-01

7.  Severe alpha-1 antitrypsin deficiency in composite heterozygotes inheriting a new splicing mutation QOMadrid.

Authors:  Beatriz Lara; Maria Teresa Martínez; Ignacio Blanco; Cristina Hernández-Moro; Eladio A Velasco; Ilaria Ferrarotti; Francisco Rodriguez-Frias; Laura Perez; Irene Vazquez; Javier Alonso; Manuel Posada; Beatriz Martínez-Delgado
Journal:  Respir Res       Date:  2014-10-07
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.